Association between early dexamethasone administration and mortality in SARS-CoV-2 infection: A cohort study
Administering dexamethasone within the first seven days of SARS-CoV-2 infection may be associated with a higher risk of death in hospitalized patients with severe pneumonia. These findings emphasize the importance of carefully timing corticosteroid treatment in COVID-19 patients.
Authors
- Renata Báez-Saldaña (ORCID: https://orcid.org/0000-0002-9582-1666)
- Lina Marcela Barranco‐Garduño
- Thalia Berenice Jacobo-Vargas
- Uriel Rumbo‐Nava (ORCID: https://orcid.org/0000-0003-2714-9422)
- Juan Carlos Neri-Salvador
- Ana Laura Bazany-Rivero
- Ernesto Murillo-Trejo
Institutions
- Instituto Nacional de Enfermedades Respiratorias (MX)
Publication Details
- Journal
- Journal of Infection and Public Health
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1016/j.jiph.2025.103066
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00